After signing up, you'll start to receive regular news updates from us.
Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease
Complete the form below to unlock access to ALL audio articles.
Two studies by researchers at the Sanders-Brown Center on Aging find similar results with different mouse models
Researchers from the Sanders-Brown Center on Aging at the University of Kentucky have been able to confirm anecdotal information on patients with both Alzheimer's disease (AD) and cerebrovascular disease (CVD) using mouse models in two different studies.
The findings of these two studies, which were recently published in Acta Neuropathologica and Alzheimer's Research & Therapy, have potentially significant implications for patients with both disorders.
Both papers studied CVD in Alzheimer's disease mouse models using different lifestyle factors.
Paul Murphy, Ph.D, and his group studied the combined effects of type 2 diabetes, Alzheimer's disease, and cerebrovascular disease in a novel mouse genetic model.
Donna Wilcock, Ph.D, and her group used a different mouse model to study the effects of Alzheimer's disease and hyperhomocysteinemia on cognition. An elevated level of homocysteine is associated with a number of disease states, including CVD.
According to Wilcock, both papers came to similar conclusions.
"We found that, while the primary Alzheimer's pathologies were unchanged, the learning and memory outcomes were significantly worse. In other words, in our mouse models, the cognitive effects of Alzheimer's disease combined with cerebrovascular disease were compounded both in terms of severity and the speed of decline," Wilcock says.
Murphy emphasizes the significance of the findings, particularly since approximately 40% of Alzheimer's patients also have cerebrovascular disease.
"We are really excited about these results," Murphy said. "Until now, we have had almost no way to study how Alzheimer's and cerebrovascular disease interact. These new mouse models give us a way to test ideas about the disease, and ultimately develop ways to treat it."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
University of Kentucky press release
Publication
Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun, Donna M Wilcock. ß-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimer's Research & Therapy, Published June 9 2014. doi: 10.1186/alzrt262
